ReviewAdvanced biomedical research2026
The Pivotal Role of miR-770 in Solid Tumors Carcinogenesis.
Review in Advanced biomedical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are known as potential biomarkers for cancer detection and therapeutic management owing to their epigenetic significance in gene expression and other cellular functions. In this review, evidence has been collected to reach the clinical effect and molecular mechanism of miR-770 in various cancers. MiR-770 dysregulation in different malignancies like breast cancer, colorectal cancer, gastric cancer, glioma, liver cancer, lung cancer, oral cancer, prostate cancer, and ovarian cancer has shown a significant decrease or increase in its expression, which indicates it acts as a tumor suppressor or oncogene. MiR-770 participates in cell growth, migration, and invasion via the cellular pathway, WNT (wingless-type MMTV integration site family)/β-catenin signaling pathways, Toll-like receptor signaling pathway, mitogen-activated protein kinases (MAPK) signaling pathway, phosphatidylinositol 3kinase (PI3K)-protein kinase B (AKT) signaling pathway, Notch signaling pathway, erythroblastic leukemia viral oncogene homolog (ErbB) signaling pathway, transforming growth factor-beta (TGF-beta) signaling pathway, Insulin signaling pathway, ubiquitin-dependent proteolysis, Neurotrophin signaling pathway, vascular endothelial growth factor (VEGF) signaling pathway, and T cell and B cell receptor signaling pathway. In the present review, MiR-770 has been introduced as a potential marker in the prognosis of various cancers as well as in the early identification of tumor formation, progression, and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.